Cite
HARVARD Citation
Ferguson, L. et al. (2022). Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease—results of the Immune Metabolic Associations in Psoriatic Arthritis study. Rheumatology. pp. 1026-1034. [Online].